Efalizumab-induced subacute cutaneous lupus erythematosus - 09/08/11
Genentech funded the pilot study using efalizumab in patients with biopsy-proven oral erosive lichen planus. Disclosure: This article is completely self-generated and has not received any outside funding. This article only reflects the views of its author. Dr Heffernan is currently director of the Washington University School of Medicine Dermatology Clinical Trials Unit. Dr Heffernan and/or the Washington University School of Medicine Dermatology Clinical Trials Unit has been active in industry-sponsored research. Dr Heffernan has been a paid investigator, lecturer, and/or consultant for Abbott, Amgen, Biogen-IDEC, Centocor, and Genentech. |
Vol 54 - N° 5S
P. S242-S243 - mai 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?